Seegene Showcased its Multiplex Technology at ADLM 2024

- Exhibited multiplex PCR testing technologies that provide comprehensive results from a single test - Presented high-multiplex assays and automated testing systems - Introduced the SG OneSystemTM business, the company's global technology-sharing initiative SEOUL, South Korea , Aug. 5, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, showcased its key products and systems at the Association for Diagnostics & Laboratory Medicine 2024 (ADLM 2024) under the exhibition theme " One Sample , Many Answers.

" The event was held in Chicago from July 30 to August 1 . The company unveiled its lineup of high-multiplex real-time PCR products designed to identify multiple targets in a single test. These assays include IVDR assays sold outside the USA for diagnosing respiratory infections (RP), gastrointestinal tract infections (GI), sexually transmitted infections (STI), human papillomavirus infections (HPV), and antimicrobial resistance (AMR).

Seegene's testing process was also displayed on the video screens at the company's exhibition booth. In addition to its flagship assay lineup, Seegene showcased the Seegene STARlet-AIOSTM (AIOS), its automated testing systems, and Seegene NIMBUS, which offer diverse automation solutions tailored to the size and needs of various testing labs. The AIOS features a modular design that seamlessly integrates existing instruments such as nucleic acid extraction equipment, .